The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey.The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg p.o/day) if they had advanced stage ALK- or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety. In this EAP, lorlatinib showed systemic activity in patients with advanced ALK+ or ROS1+ NSCLC, regardless of CNS metastases and previous TKI treatment. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1166
Authors: S. Kilickap, U. Demirci, F. Bugdayci, D. Tural, T. Korkmaz, S. Paydas, C. Yilmaz, H. Turna, A. Sezer, H. Yesil Cinkir, K. Okutur, M. Erman, Y. Eralp, D. Cabuk, A. Isikdogan, A. Demirkazik, A. Karaoglu, D. Yazilitas, F. Cay Senler, P.F. Yumuk, H. Coskun, I. Yildiz, I. Oztop, I. Beypinar, K. Aydin, M. Kaplan, N. Meydan, O.F. Olmez, O. Ozyilkan, S. Seber, C. Arslan, M.A. Sendur, I. Cicin